NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

  • Written by ACN Newswire

image

TOKYO, Apr 23, 2021 - (JCN Newswire) - Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. Filgotinib is a new oral...

Read more: Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of...